FMR LLC boosted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 89.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,621,344 shares of the company's stock after acquiring an additional 5,004,587 shares during the period. FMR LLC owned 5.16% of Cellebrite DI worth $233,988,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of CLBT. Juncture Wealth Strategies LLC grew its position in shares of Cellebrite DI by 0.8% during the 4th quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company's stock valued at $1,322,000 after purchasing an additional 505 shares in the last quarter. Strategic Advisors LLC boosted its stake in Cellebrite DI by 3.4% during the fourth quarter. Strategic Advisors LLC now owns 29,082 shares of the company's stock valued at $641,000 after buying an additional 950 shares during the period. Steward Partners Investment Advisory LLC grew its position in Cellebrite DI by 12.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company's stock worth $299,000 after buying an additional 1,463 shares in the last quarter. Quarry LP purchased a new stake in shares of Cellebrite DI in the 3rd quarter valued at about $27,000. Finally, Tower View Wealth Management LLC raised its holdings in shares of Cellebrite DI by 1.3% in the 4th quarter. Tower View Wealth Management LLC now owns 132,307 shares of the company's stock valued at $2,915,000 after acquiring an additional 1,660 shares in the last quarter. Institutional investors own 45.88% of the company's stock.
Cellebrite DI Trading Up 1.5 %
Shares of CLBT traded up $0.29 during mid-day trading on Tuesday, reaching $19.34. The company's stock had a trading volume of 769,835 shares, compared to its average volume of 1,398,842. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30. The company's fifty day moving average price is $19.48 and its two-hundred day moving average price is $20.03. The stock has a market cap of $4.63 billion, a PE ratio of -13.91, a P/E/G ratio of 4.27 and a beta of 1.44.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Research analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on CLBT. JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Lake Street Capital raised their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $28.00 target price on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $23.43.
View Our Latest Stock Analysis on CLBT
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
